Clozapine-related neutropenia and agranulocytosis in Korea: 2025 update for rethinking the role of monitoring system
Therapeutic Advances in Psychopharmacology
Published online on April 13, 2026
Abstract
Therapeutic Advances in Psychopharmacology, Volume 16, XX 2026.
Background:In February 2025, the FDA ended the mandatory Risk Evaluation and Mitigation Strategy requirements for clozapine. Korea continues mandatory hematologic testing under the Clozapine Patient Monitoring System (CPMS), yet no nationwide updates have ...
Background:In February 2025, the FDA ended the mandatory Risk Evaluation and Mitigation Strategy requirements for clozapine. Korea continues mandatory hematologic testing under the Clozapine Patient Monitoring System (CPMS), yet no nationwide updates have ...